Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
«Рожденный» ASCOT
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: артериальная гипертензия, амлодипин, периндоприл, суточное мониторирование артериального давления, фиксированные комбинации антигипертензивных препаратов.
________________________________________________
The paper presents data from an Anglo-Scandinavian Outcome Trial (ASCOT). It considers the benefits of amlodipine/perindopril in lowering blood pressure and a cardiovascular risk. It discusses the importance of central pressure as a prognostic factor and the results of a Conduit Artery Function Evaluation (CAFE), an ASCOT substudy, which has revealed the benefits of a combination of amlodipine and perindopril in its reduction. Particular attention is given to 24-hour monitoring-measured blood pressure levels as prognostically independent risk factors for cardiovascular events. The authors provide the results of the ASCOT-ABPM substudy that has defined the importance of nocturnal systolic blood pressure as an independent predictor of the development of myocardial infarction and stroke, as well as the benefit of a combination of amlodipine and perindopril in lowering nocturnal systolic blood pressure.
Key words: arterial hypertension, amlodipine, perindopril, 24-hour blood pressure monitoring, fixed-dose combinations of antihypertensive agents.
2. Диагностика и лечение артериальной гипертензии. Российский рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 3: 5–26.
3. Sever PS, Dahlof B, Poulter NR et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial J Hypertens 2001; 6: 1139–47.
4. Kjeldsen SE, Dahlof B, Devereux RB et al. Losartan Intervention for Endpoint Reduction (LIFE) Study Group: Effect of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: Losartan Intervention for Endpoint Reduction (LIFE) substudy. J Am Med Assoc 2002; 288: 1491–8.
5. London GM, Asmar RG, Rourke MF, Safar ME. REASON Project Investigators: Mechanism(s) of selective systolic blood pressure reduction after a low dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43: 92–9.
6. Williams B, Lacy PS, Thom SM et al. The CAFÉ Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT) Investigators, CAFÉ Steering Committee and Writing Committee. Circulation 2006; 113: 1213–25.
7. Бойцов С.А. Исследование ASCOT как аргумент в борьбе «нового» со «старым» и шаг к переоценке «системы ценностей». Cons. Med. 2006; 8 (8).
8. Tropeano A, Boutouyrie P, Pannier B et al. Brachial pressure-independent reduction in carotid stiffnes after long-term angiotensin-convertinge enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48 (1): 80–6.
9. O’Brien E. Is the case for ABP as a routine investigation in clinical practice not overwhelming? Hypertension 2007; 50: 284–6.
10. Dolan E, Stanton A, Thijs L, Hinedi K et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46: 156–61.
11. Perloff D, Sokolow M, Cowan R. The prognostic value of ABP blood pressure. JAMA 1983; 249: 2792–8.
12. Redon J, Campos C, Narciso ML, Rodicio JL et al. Prognostic value of ABP blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998; 31: 712–8.
13. Staessen J, Thijs L, Fagard R, O’Brien E et al. for the systolic hypertension in Europe Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282: 539–46.
14. Ohkubo T, Imai Y, Tsuji I, Nagai K et al. Prediction of mortality by ABP blood pressure monitoring versus screening blood pressure measurements: a pilot study in Ohasama. J Hypertens 1997; 15: 357–64.
15. D Ohkubo T, Hozawa A, Nagai K, Kikuya M et al. Prediction of stroke by mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population: the Ohasama study. J Hypertens 2000; 18: 847–54.
16. Clement DL, De Buyzere M, De Bacquer DA, de Leeuw PW et al. for the Office versus Ambulatory Blood Pressure (OvA) Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 207–15.
17. Verdecchia P, Reboldi G, Porcellati C, Schillaci G et al. Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. J Am Coll Cardiol 2002; 39: 878–85.
18. Verdecchia P, Angeli F, Cavallini C. Ambulatory blood pressure for cardiovascular risk stratification. Circulation 2007; 115: 2091–3.
19. Svensson P, de Faire U, Sleight P, Yusuf S. Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE sub-study. Hypertens 2001; 38: e28–e32.
20. Dolana E, Stantonb AV, Thomc S, Caulfieldd M et al on behalf of the ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens 2009; 27 (4): 876–85.
21. O’Brien E, Asmar R, Beilin L, Imai Y et al. on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21: 821–48.
22. O’Brien E, Mee F, Atkins N, O’Malley K. Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society protocol. J Hypertens 1991; 9: 573–4.
23. Physicians Desk Reference. NJ: Medical Economics Company; 2008.
ГОУ ВПО Московский государственный медико-стоматологический университет Минздравсоцразвития РФ
*ostroumova.olga@mail.ru
________________________________________________
O.D.Ostroumova*, O.V.Bondarets
Moscow State University of Medicine and Dentistry
*ostroumova.olga@mail.ru